Open AccessIbero-American Expert Consensus on Squamous Cell Carcinoma of the Head and Neck Treatment in Patients Unable to Receive Cisplatin: Recommendations for Clinical Practice
Author(s) -
Agustín Falco,
Thiago Bueno de Oliveira,
Jon Cacicedo,
Aylen Vanessa Ospina,
Miguel Ángel Ticona,
Héctor Galindo,
Manuela M. Pereira,
José Luis Aguilar-Ponce,
Antonio Rueda-Domínguez,
Tannia Soria,
Ángel Cequier,
Lara Iglesias,
T. Sowley,
Ricard Mesı́a,
Neck Cancer
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s322411
Subject(s) - medicine , cisplatin , oncology , ototoxicity , radiation therapy , disease , chemotherapy , head and neck squamous cell carcinoma , quality of life (healthcare) , nephrotoxicity , intensive care medicine , head and neck cancer , toxicity , nursing
Cisplatin is the standard of treatment for squamous cell carcinoma of the head and neck (SCCHN) that has demonstrated efficacy, either in locally advanced disease when combined with radiotherapy at high doses, or in metastatic/recurrent disease when combined with other agents. However, the usual toxicities related to cisplatin, such as neurotoxicity, nephrotoxicity, ototoxicity, and hematologic toxicities, especially when high doses have been administered, have important implications in the patients' quality of life. The decision to administer cisplatin depends on several patient factors, such as age, performance status, weight loss, comorbidities, previous toxicities, chronic viral infection, or even the current SARS-CoV-2 pandemic. In order to establish recommendations for the management of patients with SCCHN, a group of experts in medical and radiation oncology from Spain and Latin-American discussed how to identify patients who are not candidates for cisplatin to offer them the most suitable therapeutic alternative.